Idorsia's Dual Orexin Receptor Antagonist Wins Inaugural Prix Galien Bridges Award for Insomnia Treatment Innovation
Key Insights
Idorsia's dual orexin receptor antagonist (search) has been awarded the inaugural Prix Galien Bridges Award in the "Best Biotechnology & Pharmaceutical Product" category for its breakthrough approach to treating insomnia disorder (search).
The drug represents the first and only dual orexin receptor antagonist (search) approved in Europe for insomnia treatment, developed after more than 10 years of research involving the synthesis and characterization of over 25,000 compounds.
The treatment targets the orexin (search) system to induce physiological sleep while maintaining rapid onset and sufficient duration to cover the entire night without morning carry-over effects.
Idorsia Ltd announced that its novel dual orexin receptor antagonist (search) has received the inaugural Prix Galien Bridges Award in the "Best Biotechnology & Pharmaceutical Product" category, marking a significant recognition for the first and only drug of its kind approved in Europe for treating insomnia disorder (search).
The Prix Galien Awards, created in 1970 and regarded as the equivalent of the Nobel Prize for the life sciences industry, recognize groundbreaking medicines that advance patient care through scientific innovation. The inaugural Bridges Award specifically honors breakthrough innovations in life sciences across 16 countries and Africa.
Decade-Long Development Journey
The development of this dual orexin receptor antagonist (search) represents a remarkable scientific achievement spanning more than a decade. Dr. Martine Clozel, Idorsia's Chief Scientific Officer, revealed that the research team began investigating orexin (search) and orexin receptors immediately after their initial description in 1998.
"Our initial work led to the understanding that antagonism of the orexin (search) system induced a very physiological sleep," Clozel explained. The team's ambitious goal was to design a dual orexin receptor antagonist (search) that would achieve rapid onset of effect and sufficient duration to cover the entire night at optimally effective doses while avoiding morning carry-over effects.
This extensive research effort required the synthesis and characterization of more than 25,000 compounds before arriving at the final molecule that has now been recognized with the Prix Galien Bridges Award.
Understanding the Orexin System
The orexin (search) system plays a crucial role in regulating wake and sleep signaling through intricate neural circuitry in the brain. This system comprises two forms of orexin neuropeptides—orexin A and orexin B—which are small protein-like molecules that enable communication between neurons in the brain.
Orexin (search) promotes wakefulness through its receptors OX1R (search) and OX2R (search), stimulating targeted neurons in the wake system and leading to the release of several chemicals including serotonin, histamine, acetylcholine, and norepinephrine. Under normal circumstances, orexin levels rise throughout the day to promote wakefulness and fall at night. However, overactivity of the wake system serves as an important driver of insomnia.
Addressing a Significant Medical Need
Insomnia disorder (search) represents a substantial healthcare challenge, defined as difficulty initiating or maintaining sleep that causes clinically significant distress or impairment in important areas of daytime functioning. The condition must be present for at least three nights per week over a period of at least three months and occur despite adequate opportunity to sleep.
In Switzerland, insomnia disorder (search) affects an estimated 9.2% of the working-age population. Unlike short periods of poor sleep, insomnia disorder is a persistent condition that negatively impacts both physical and mental health, affecting daytime performance and various aspects of daily life including concentration ability, mood, and energy levels.
Studies have demonstrated that in patients with insomnia, brain regions associated with wakefulness remain more active during sleep, representing a state of overactive wake signals. The goal of treating insomnia is to improve both sleep quality and quantity while enhancing daytime performance and avoiding side effects or after-effects the following morning.
Clinical Innovation and Patient Impact
Idorsia's research team concluded that antagonism of the orexin (search) system is key to maintaining natural sleep architecture in patients with insomnia. The team developed dual antagonists specifically designed to provide rapid onset of action with duration sufficient to bridge the night while remaining short enough to minimize negative residual activity the next morning at optimally effective doses.
"The molecule which has now been recognized with the Prix Galien Bridges Award" improves "not only the nights of patients with insomnia disorder (search), but also most importantly their daytime functioning," according to Clozel.
Market Access and Future Outlook
Bettina Blosse, General Manager of Idorsia Nordics, emphasized the company's commitment to making this innovative treatment accessible to patients. "My team is working to make this medicine accessible to all patients in the Nordic region," she stated, highlighting the recognition as "a wonderful endorsement of Idorsia's commitment to innovation in healthcare."
The currently recommended treatment approaches for insomnia include sleep hygiene, cognitive behavioral therapy, and pharmacotherapy. Idorsia's dual orexin receptor antagonist (search) represents a novel addition to the therapeutic armamentarium, offering a mechanistically distinct approach to addressing this prevalent sleep disorder.
This recognition underscores the potential of targeting the orexin (search) system as a therapeutic strategy for sleep disorders and validates Idorsia's extensive research investment in understanding the fundamental mechanisms underlying sleep and wakefulness regulation.